5-HT3 Antagonist Ondansetron Increases apoE Secretion by Modulating the LXR-ABCA1 Pathway

5-HT3 Antagonist Ondansetron Increases apoE Secretion by Modulating the LXR-ABCA1 Pathway

Apolipoprotein E (apoE) is linked to the risk for Alzheimer’s disease (AD) and thus has been suggested to be an important therapeutic target. In our drug screening effort, we identified Ondansetron (OS), an FDA-approved 5-HT3 antagonist, as an apoE-modulating drug. OS at low micromolar con...

Full description

Bibliographic Details
Main Authors: Motoko Shinohara, Mitsuru Shinohara, Jing Zhao, Yuan Fu, Chia-Chen Liu, Takahisa Kanekiyo, Guojun Bu
Format: Article
Language:English
Published: MDPI AG 2019-03-01
Series:International Journal of Molecular Sciences
Subjects:
apoE
astrocytes
Alzheimer’s disease
ondansetron
LXR
ABCA1
Online Access:https://www.mdpi.com/1422-0067/20/6/1488

Internet

https://www.mdpi.com/1422-0067/20/6/1488

Similar Items